Diabetes Drug for Bile Acid Diarrhea Bests Standard of Care in Small Trial
(MedPage Today) -- Glucagon-like peptide 1 (GLP-1) receptor agonist liraglutide (Victoza, Saxenda) may be superior to colesevelam (Welchol) for reducing stool frequency in patients with moderate-to-severe bile acid diarrhea, a small randomized... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - July 21, 2022 Category: Gastroenterology Source Type: news
colesevelam (Welchol)
Title: colesevelam (Welchol)Category: MedicationsCreated: 8/9/2004 12:00:00 AMLast Editorial Review: 8/8/2019 12:00:00 AM (Source: MedicineNet Cholesterol General)
Source: MedicineNet Cholesterol General - August 8, 2019 Category: Cardiology Source Type: news
CrossFit for T2D; GSM in Cancer Guidelines; Generic Welchol
(MedPage Today) -- News and commentary from the endocrinology world (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - May 18, 2018 Category: Endocrinology Source Type: news
Welchol (Colesevelam Hcl) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 27, 2016 Category: Drugs & Pharmacology Source Type: news
Utilization and Outcomes of Colesevelam HCl in the GE EMRUtilization and Outcomes of Colesevelam HCl in the GE EMR
Does colesevelam decrease A1c in clinical practice as well as it did in clinical trials? BMC Endocrine Disorders (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 23, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Statin Doesn’t Impair Colesevelam’s Glucose-Lowering Ability
Read the full story on MD Consult:
Statin Doesn’t Impair Colesevelam’s Glucose-Lowering Ability (Source: MD Consult: News: Top Stories)
Source: MD Consult: News: Top Stories - June 7, 2013 Category: Journals (General) Source Type: news
Cardiovascular Complications of T2DM: Drugs to Watch
Colesevelam helps reduce serum glucose levels and also lowers LDL-C in patients with type 2 diabetes. In patients on stable levels of antihyperglycemic medication, bromocriptine reduces the relative risk of cardiovascular events. Both are included in the 2013 AACE algorithm as add-on therapy in patients on dual or triple therapy for diabetes. (Source: Consultant Live)
Source: Consultant Live - May 13, 2013 Category: Primary Care Source Type: news
Drugs Market: Comprehensive Patent Search Analysis for Vemurafenib,...
Comprehensive patent search for Vemurafenib, Colesevelam, Rifaximin, Nevirapine, Liraglutide, Vilazodone, Hexylaminolevulinic Acid and Treprostinil in new market research reports at...(PRWeb February 19, 2013)Read the full story at http://www.prweb.com/releases/drugs-comprehensive/patent-search-analysis/prweb10444767.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 19, 2013 Category: Pharmaceuticals Source Type: news
